Sign In
Buy NBTX
$38.39
-1.77 (-4.41%)
At Close: Jul 31, 2026
Data presented as a “Top-rated Abstract in Head and Neck Cancer” at the 2025 Annual Meeting of the American Society for Radiation Oncology (ASTRO) on September 29th
Melanoma Data Study Boosts J&J Partner Nanobiotix Stock On Thursday
03:46pm, Thursday, 18'th Sep 2025
Nanobiotix SA NBTX announced new results focused on patients with primary cutaneous melanoma from an ongoing Phase 1 Study.
Nanobiotix: Today's Data Readout For Radiation Therapy Enhances Bull Case
01:56pm, Thursday, 18'th Sep 2025
Nanobiotix S.A. stock has surged after strong Phase 1 data for NBTXR3 in anti-PD-1 resistant melanoma, showing high response and disease control rates. NBTX's partnership with Janssen could yield up t
Nanobiotix S.A. - Special Call
10:13am, Thursday, 18'th Sep 2025
Nanobiotix S.A. - Special Call Company Participants Joanne Choi Laurent Levy - Co-Founder, President of the Executive Board & CEO Conference Call Participants Ruoxi Liao - Guggenheim Securities, LLC,
Data show a favorable safety profile and early efficacy signals in a heavily pre-treated population whose cancer progressed after multiple prior lines of therapy including anti-PD-1 Recommended phase
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
04:15pm, Tuesday, 02'nd Sep 2025
PARIS and CAMBRIDGE, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparti
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
04:15pm, Monday, 07'th Jul 2025
PARIS and CAMBRIDGE, Mass., July 07, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-stage clinical biotechnology company pioneering physics-
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
02:00am, Wednesday, 28'th May 2025
PARIS and CAMBRIDGE, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticl
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
04:15pm, Wednesday, 21'st May 2025
PARIS and CAMBRIDGE, Mass., May 21, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage biotechnology company pioneering nanotherapeutic appr
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
02:00am, Monday, 12'th May 2025
PARIS and CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanoparticl
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
02:00am, Monday, 05'th May 2025
Results demonstrated favorable safety, injection feasibility, and encouraging oncologic outcomes in patients (n=22) with locally advanced or borderline resectable pancreatic cancer Median Overall Surv
PARIS and CAMBRIDGE, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering nanopart
Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript
04:24pm, Thursday, 03'rd Apr 2025
Nanobiotix S.A. (NASDAQ:NBTX ) Q4 2024 Results Conference Call April 3, 2025 8:00 AM ET Company Participants Craig West - Senior Vice President, Investor Relations Laurent Levy - Co-Founder and Chief
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
04:15pm, Wednesday, 02'nd Apr 2025
Global development program for JNJ-1900 (NBTXR3) proceeding as planned, with opportunity to address one of the largest untapped markets in oncology through lead programs in head and neck cancer and lu
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
02:00am, Monday, 31'st Mar 2025
Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST Conference call and webcast scheduled for Thursday, April 3, 2025, at 8:00 am EDT / 2:00 pm CEST
